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Abstract
Angiogenesis plays an essential role in tumor growth and metastasis and is a promising target for cancer therapy.
Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis. The present study was designed to
determine the role of VEGF in tumor growth and metastasis using RNA interference (RNAi) technology. Four small
interfering RNA (siRNA) sequences for the VEGF gene were cloned into expression plasmids and transfected into
human colorectal carcinoma (CRC) SW620 cells. Stable transfection of these plasmids decreased VEGF protein
expression, leading to the potent suppression of tumor cell proliferation, migration, invasion, and angiogenesis
in vitro. Furthermore, in subcutaneous and intrasplenic/portal injection models involving athymic nude mice,
the tumor growth and metastasis of SW620 cells expressing VEGF siRNA were significantly inhibited compared
with untransfected cells or cells transfected with control vector alone. Immunohistochemical analyses of tumor
sections revealed a decreased vessel density and decreased VEGF expression in the animals where siRNA
against VEGF were expressed. These results indicate that RNAi of VEGF can be an effective antiangiogenic strat-
egy for CRC.
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Introduction
Colorectal carcinoma (CRC) is the third leading cause of cancer in
both men and women and accounts for about 10% of all new cancer
cases and cancer deaths in the US [1]. Whereas the overall 5-year
survival rate for patients with CRC is 64%, the rate drops to 10%
or less in patients with metastatic disease [1]. By the time of diagno-
sis, 19% of CRC cases are metastatic.
Angiogenesis is an important step in the outgrowth of a primary
tumor and a key source for hematogenous tumor dissemination, pro-
gression, and metastasis. Many potential angiogenic factors have been
characterized, including vascular endothelial growth factor (VEGF)
and platelet-derived endothelial cell growth factor [2,3]. VEGF is
perhaps the most prominent factor, and it has been extensively stud-
ied for its role in the invasion and metastasis of cancer cells. For in-
stance, in situ hybridization studies have demonstrated that VEGF
mRNA is expressed in the majority of human cancers [4–12].
RNA interference (RNAi) is the sequence-specific, posttranscrip-
tional gene-silencing method initiated by double-stranded RNA that
are homologous to the gene being suppressed. Double-stranded
RNA are processed by Dicer, a cellular RNase III, to generate du-
plexes of ∼21 nt with 3′-overhangs [small interfering RNA (siRNA)],
which mediate sequence-specific mRNA degradation [13,14]. RNAi
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technology, especially chemically synthesized siRNA, is currently be-
ing evaluated not only as a powerful tool for functional genomic
analyses but also as a potentially useful method to develop highly
specific gene-silencing therapeutics. Previous studies have shown that
inhibition of VEGF by siRNA decreases tumor growth in several an-
imal models [15,16].
The high efficiency and specificity of RNA-mediated interference
has made it a powerful and widely used tool for the analysis of gene
function. In this report, we used a vector-based VEGF siRNA expres-
sion system to suppress the expression of VEGF in SW620 human
CRC cells and to evaluate its therapeutic efficacy in a xenograft model.
The vector-based RNAi technology may overcome the limitations of
transience and high cost associated with synthetic siRNA and, more
importantly, it may make in vivo testing possible.
Materials and Methods
Cell Culture
ECV304 cells and the CRC cell line SW620 (Laboratory of Cell
Biology, Xiangya Medical School, Changsha, China) were main-
tained in RPMI 1640 medium containing 10% fetal bovine serum,
100 μg/ml penicillin, and 100 μg/ml streptomycin. Routine testing
confirmed that the cells were free of Mycoplasma and viral contami-
nants during the entire study period.
Generation of VEGF siRNA Expression Plasmids
We selected siRNA sequences as reported by Elbashir et al. [17].
We used the following procedure to design the VEGF siRNA: 1)
search for the sequences 5′-AA(N19) or 5′-NA(N19), where N is
any nucleotide, in the intended mRNA sequence, and use only those
sequences that occur within an open reading frame, preferably 50 to
100 nt downstream of the start codon, and show 47% or 52% G/C
content; 2) perform a BLAST search with the selected siRNA se-
quences against expressed sequence tag libraries to ensure that only
a single gene is targeted; and 3) search for any predicted secondary
structure of the target mRNA that might inhibit siRNA binding.
Four siRNA targeting human VEGF and one scrambled siRNA (used
for a negative control) with the following sense and antisense se-
quences were used: VEGF siRNA no. 1, 5′-GGCGTCGCACT-
GAAACTTT-3′ (sense) and 5′-AAAGTTTCAGTGCGACGCC-3′
(antisense); VEGF siRNA no. 2, 5′-ACCTCACCAAGGCCAG-
CAC-3′ (sense) and 5′-GTGCT GGCC TTGG T GAG GT-3′ (an-
tisense); VEGF siRNA no. 3, 5′-GGG CAGAA TCA TCA C
GAAG-3′ (sense) and 5′-CTTCGTGATGATTCTGCCC-3′ (anti-
sense); VEGF siRNA no. 4, 5′-GGCCAGCACATAGGAGAGA-3′
(sense) and 5′-TCTCTCCTATGTG CTGGCC-3′ (antisense); and
negative VEGF siRNA control, 5′-GACTTCATAAGGCGCATGC-
3′ (sense) and 5′-GC ATGCGCCTTATGAAGTC-3′ (antisense).
All siRNA were designed and synthesized by Wuhan Genesil Bio-
technology Co., Ltd., Wuhan, China. Sense and antisense primers
containing the sense siRNA sequence, 9 bp loop sequence, anti-
sense siRNA sequence, and RNA polymerase III terminator se-
quence were created with BamHI and HindIII restriction sites on
the 5′ and 3′ ends, respectively. These primers were annealed and
inserted into pGenesil-1 (Wuhan Genesil Biotechnology Co, Ltd.)
downstream of the H1 RNA polymerase III promoter, following
the manufacturer’s instructions. The resultant plasmids containing
siRNA sequences 1, 2, 3, and 4 and negative control sequences were
named pSihVEGF-1, pSihVEGF-2, pSihVEGF-3, pSihVEGF-4,
and pHK, respectively.
Stable Transfection of siRNA
SW620 cells were stably transfected with pSihVEGF-1, pSihVEGF-2,
pSihVEGF-3, pSihVEGF-4, or pHK in the presence of Lipofectamine
2000 (Invitrogen, Guangzhou, China) following the manufacturer’s
instructions and placed under G418 selection for 4 weeks. Surviving
colonies were isolated and expanded. Surviving colonies containing
pSihVEGF-1, pSihVEGF-2, pSihVEGF-3, pSihVEGF-4, or pHK
were named SihVEGF-1, SihVEGF-2, SihVEGF-3, SihVEGF-4, or
HK, respectively.
VEGF ELISA and Western Blot Analysis
The secretion of VEGF by stably transfected cells was determined
using a Quantikine human VEGF Immunoassay kit (R&D Systems,
Minneapolis, MN) according to the manufacturer’s instructions. All
the experiments were done in triplicate.
For analysis of intracellular VEGF protein levels, untransfected
and transfected SW620 cells were cultured in 100-mm dishes and
when cells reached 80% confluence, cell lysates were collected and
protein concentrations determined using the BCA Protein Assay Re-
agent Kit (Pierce Corporation, Rockford, IL). The protein samples
(50 μg) were boiled for 3 minutes before being loaded onto a
7.5% SDS–polyacrylamide gel and, after electrophoresis, the proteins
were transferred to a nitrocellulose membrane (Amersham, Piscat-
away, NJ). The membranes were probed with primary antibody fol-
lowed by peroxidase-conjugated secondary antibody and visualized
by the enhanced chemiluminescene detection system (Amersham)
according to the manufacturer’s instructions.
MTT Assay
Cell proliferation was measured by the MTT assay. SW620,
SihVEGF-4, and HK cells were seeded in 24-well plates at a density
of 1 × 104 cells/well. After a 24-hour incubation, 200 μl of 5 mg/μl
solution of MTT (Sigma, Guangzhou, China) in PBS was added to
each well. The plates were then incubated for 4 hours at 37°C. The
precipitate was then solubilized in 100% dimethylsulfoxide (Sigma),
100 μl/well, and shaken for 15 minutes. Absorbance of each well
was measured on a microplate reader (Wellwash MK2; Labsystems
Dradon, Helsinki, Finland) at a wavelength of 492 nm. All experi-
ments were done in quadruplicate.
Flow Cytometry
Flow cytometry was used to further assess the mechanisms respon-
sible for the decreased proliferation seen in SW620, SihVEGF-4, and
HK cells. The harvested cells were washed with PBS, fixed with 70%
ethanol, treated with RNase A (Sigma) and then stained with propi-
dium iodide (Sigma). Finally, cell cycle analysis was carried out using
a flow cytometer.
Adhesion Assay
The SW620, SihVEGF-4, and HK cells were seeded in quadrupli-
cate at a density of 1 × 104 cells/well in 96-well plates coated with
BSA (10 g/l), Matrigel (50 mg/l), or fibronectin (Fn) (10 mg/l). The
cells were cultured at 37°C for 60 minutes, and the MTT assay was
performed as above.
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Tumor Cell Adherence to ECV304
ECV304 cells were plated onto 96-well plates at a density of 5 ×
104 cells/well. After 48 hours, the supernatant was aspirated and
SW620, SihVEGF-4, and HK cells were plated at a density of 5 ×
104 cells/well. After 30 minutes, the wells were gently washed twice
with PBS to remove unattached cells, and 100 μl of rose bengal
(25%) was added for 5 minutes. The supernatant was aspirated,
the wells were gently washed twice with PBS, and finally 200 μl
95% ethanol/PBS (1:1) was added. After 20 minutes, the absorbance
at 570 nm was recorded.
Migration Assay
The SW620, SihVEGF-4, and HK cells were plated onto 12-well
plates at a density of 8 × 104 cells/well. After forming monolayers,
cells were wounded by manual scraping with a 200-micropipette tip.
The culture medium was then replaced with fresh, serum-free medium.
Wound closure was monitored at various time points by observation
under a microscope and the degree of cell migration was quantified
by the ratio of gap distance at 24 hours to that at 0 hour. The experi-
ment was done in triplicate.
Invasion Assay
The invasion assays with SW620, SihVEGF-4, and HK cells were
performed using Transwell polycarbonate membrane inserts in 24-
well plates (Corning, Lowell, MA) following the manufacturer’s in-
structions. Briefly, the underside of each polycarbonate microporous
membrane was coated with Matrigel (1:100) at 37°C for 5 minutes
and allowed to sit overnight. Then, 50 μl Matrigel (1:30) and 200 μl
sterile water were added to the upper compartment at 37°C. After
2 days, 200 μl of the invasion buffer [2 ml BSA (2%) + 38 ml RPMI
1640] was added into the upper compartment and, 1 hour later, the
upper compartment fluid was aspirated. SW620, SihVEGF-4, or HK
cells at a density of 5 × 104 cells/well were added into the upper com-
partment, and 800 μl of the Fn solution (10 μg/ml) was added into
the lower compartment. The cells were allowed to migrate for
48 hours. The inserts were then fixed in 10% formalin, stained with
hematoxylin and eosin, and rinsed by dipping in water. The cells on
the upper surface of the membrane were removed with a cotton bud.
The membranes were air-dried overnight, excised from the insert,
and mounted onto glass slides for microscopic analysis. The migrated
cells were counted at high-power magnification (×40) from four ran-
domly selected fields. Each experiment was repeated three times.
In Vitro Angiogenesis Assay
The test was performed using the In vitro Angiogenesis Assay Kit
(Chemicon International, Temecula, CA) following the manufac-
turer’s instructions. Briefly, 96-well plates were coated with cold so-
lution (50 μl/well of a solution containing 900 μl of ECMatrix per
100 μl of 10× diluent buffer), which was allowed to polymerize at
room temperature for about 60 minutes. Then, wells were seeded
with 100 μl of a 5 × 104 cells/ml suspension of ECV304,
ECV304 transiently transfected with pHK, or ECV304 transiently
transfected with pSihVEGF-4. Tube formation was assessed after
12 hours.
Murine Xenograft Model
Male BALB/c athymic nude mice, 4 to 6 weeks old, were injected
subcutaneously with 2 × 106 SW620, SihVEGF-4, or HK cells. Tumor
diameters were measured at regular intervals with digital calipers, and
the tumor volume in mm3 was calculated by the formula: volume =
(width)2 × length/2 [18]. Every group had three mice. Animal experi-
ments in the present study were performed in compliance with
the guidelines of the Institute for Xiangya Medical School, Central
South University.
Experimental liver metastases were generated by intrasplenic/portal
injection of tumor cells (SW620, SihVEGF-4, or HK cells) as de-
scribed previously [19]. The mice were inoculated with 2 × 106 cells
and splenectomized 1 minute later. Every group had three mice. Ani-
mals were killed 5 weeks later, and liver metastases were counted im-
mediately without prior fixation.
Immunohistochemical Analysis
Immunohistochemical staining for CD31 and microvessel count-
ing of CD31-positive vessels were performed as described previously
[20]. Immunohistochemical determination of VEGF was also per-
formed as described previously [21].
Statistical Analysis
All results are expressed as means ± SD. Statistical analyses were
performed using the Statistical Package for the Social Sciences (SPSS
Inc., Chicago, IL), and statistical significance was set at P < .05.
Results
Effects of VEGF siRNA on the Expression of VEGF
Four VEGF siRNA–expressing plasmids (plasmids 1, 2, 3, and 4)
and one negative control plasmid (pHK) were constructed using the
pGenesil-1 vector. The pGenesil-1 vector encodes enhanced green
fluorescence protein, so that if the VEGF siRNA–expressing plas-
mids are successfully transfected into the SW620 cells, they can be
detected by fluorescence microscopy. As shown in Figure 1, the trans-
fections were successful, and five stably transfected cell lines could be
constructed. The VEGF protein levels were measured by ELISA and
Western blot analysis. As shown in Figure 2A, VEGF siRNA signif-
icantly inhibited VEGF expression in four cell lines as measured by
ELISA: SihVEGF-1 (74.75% of expression in untransfected cells),
SihVEGF-2 (61.72%), SihVEGF-3 (69.21%), and SihVEGF-4
(97.46%). The inhibition reached statistical significance (P < .001),
whereas the slight inhibition observed in HK cells (2.04%) (P >
.05). Western blot analysis confirmed the inhibition of VEGF expres-
sion by the four VEGF siRNA constructs (Figure 2B). Subsequent ex-
periments focused on the VEGF siRNA no. 4 because it was the most
effective at inhibiting VEGF expression.
Effects of VEGF siRNA on Tumor Cell Proliferation
The biological effects of the VEGF siRNA were first determined
using cell proliferation assays. As shown in Figure 3 SihVEGF-4 cell
proliferation was significantly inhibited at days 3 and 4 (P < .001,
compared with the controls), whereas there was little difference be-
tween the negative control cells (HK) and untransfected SW620 cells
over the entire experimental period (P > .05). The VEGF siRNA were
also found to have an effect on the cell cycle (Figure 4): 67.0% of
SihVEGF-4 cells were in the G1 phase, which was significantly higher
than the fraction for HK cells (54.5%) or untransfected SW620
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cells (50.8%), suggesting that the VEGF siRNA arrests cells in the
G1 phase.
Effects of the VEGF siRNA on Tumor Cell Adhesion
Suppressing VEGF expression had a clear inhibitory effect on the
adhesion of transfected colon cancer cells to the extracellular matrix
(ECM) [Matrigel and Fn] and to ECV304. The percentages of ad-
hesion to ECM were as follows: SW620, 36.23% (Fn) and 86.42%
(Matrigel); HK, 38.84% (Fn) and 84.77% (Matrigel); and SihVEGF-4,
9.13% (Fn) and 41.2% (Matrigel) (Figure 5A). The tumor cell
lines showed different absorbance abilities: SW620, 0.611; HK,
0.585; and SihVEGF-4, 0.283 (Figure 5B). Thus, the adhesion of
SihVEGF-4 to ECM and to ECV304 cells was significantly sup-
pressed (P < .001), whereas there was little difference between un-
transfected cells and negative control HK cells (P > .05).
Effects of VEGF siRNA on Tumor Cell Migration
As shown in Figure 6, the migration distance of untransfected
SW620, HK, and SihVEGF-4 was 1.8, 1.75, and 0.83 mm, respec-
tively. These findings suggest that the migration of SihVEGF-4 was
significantly suppressed (P < .001), whereas there was little difference
between untransfected cells and the negative control (HK) (P > .05).
Effects of VEGF siRNA on Tumor Cell Invasion
As shown in Figure 7A, for each 400× field under the microscope,
the number of migrated SihVEGF-4 cells was 246 ± 23, significantly
Figure 1. Transfection of VEGF siRNA into cells. The pGenesil-1 vector was used to construct plasmids expressing VEGF siRNA and
EGFP as a fluorescence probe. Stably transfected SW620 cells (SihVEGF-1, SihVEGF-2, SihVEGF-3, SihVEGF-4, and HK control cells)
could be easily identified by fluorescence microscopy.
Figure 3. Effects of VEGF siRNA on tumor cell proliferation as
measured by the MTT assay. *P > .05, P < .001.
Figure 2. Effects of VEGF siRNA on VEGF expression in trans-
fected cells. (A) ELISA was used to measure the amount of VEGF
in supernatants from SihVEGF-1, SihVEGF-2, SihVEGF-3, SihVEGF-4,
HK, and untransfected SW620 cells. *P > .05, P < .001. (B)
Western blot analysis was used to measure the amount of VEGF
in SihVEGF-1, SihVEGF-2, SihVEGF-3, SihVEGF-4, HK, and untrans-
fected SW620 cells.
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lower than the number of untransfected cells (446 ± 15) and the neg-
ative control HK cells (438 ± 14) (P < .001). In addition, there was
little difference between untransfected cells and the negative control
(HK) (P > .05).
Effects of VEGF siRNA on Angiogenesis In Vitro
As shown in Figure 7B, in vitro tube formation of ECV304 cells
transiently transfected with pSihVEGF-4 was 35 ± 4 per 100× field,
which was significantly lower (P < .001) compared with untrans-
fected ECV304 (117 ± 9) and ECV304 transiently transfected with
pHK (121 ± 5). Moreover, there was little difference between un-
transfected ECV304 and ECV304 transiently transfected with
pHK (P > .05).
Effects of VEGF siRNA on CRC Tumor Growth
and Metastasis In Vivo
As shown in Figure 8, SW620 and HK cells grew rapidly. In contrast,
tumor formation was significantly delayed in the case of SihVEGF-4.
Figure 4. Effects of VEGF siRNA on tumor cell cycle distribution.
Figure 5. Effects of VEGF siRNA on tumor cell adhesion. (A) Tumor
cell adhesion to ECM (Fn and Matrigel). *P > .05, P < .001. (B)
Tumor cell adhesion to ECV304. *P > .05, P < .001.
Figure 6. Effects of VEGF siRNA on tumor cell migration. *P> .05,
P < .001.
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In addition, the SihVEGF-4 tumors were significantly smaller than
those in untransfected SW620 cells and in the HK negative control
(P < .001).
In a model of CRC liver metastasis, the untransfected SW620 and
HK groups showed an increased number of metastatic tumors com-
pared to the SihVEGF-4 group, and their body weight decreased sig-
nificantly after 28 days (Figure 9). In contrast, metastatic tumors in
the SihVEGF-4 group formed in only one nude mouse (n = 3) and
the body weight of nude mice decreased slowly from 28 days.
Immunohistochemical Findings
Tumor tissue from mice was excised and subjected to immunohis-
tochemical staining. As shown in Figure 10, the microvascular density
(MVD) values (per 200× field) of subcutaneous tumors in SW620,
HK, and SihVEGF-4 cell lines were 14 ± 2, 12 ± 1, and 4 ± 1, re-
spectively. The MVD values of liver metastatic tumors in SW620,
HK, and SihVEGF-4 cell lines were 17 ± 2, 15 ± 3, and 7 ± 2, re-
spectively. These results indicate that CD31-positive vessels were
abundant in subcutaneous tumors and liver metastatic tumors in the
SW620 and HK lines (P > .05), whereas vessel density in both tumor
types was significantly decreased in the SihVEGF-4 group (P < .001).
VEGF staining was much higher in subcutaneous tumor and liver
metastatic tumors of SW620 and negative control cells (Figure 11).
In contrast, VEGF staining was significantly decreased in both tumor
types for the SihVEGF-4 group. Quantitative data for VEGF immuno-
histochemical staining was analyzed using Image Pro Plus 6.0 (Media
Cybernetics, Shanghai, China). The integrated optical density (IOD)
values of subcutaneous tumors of SW620, HK, and SihVEGF-4
cells were 1900.75 ± 84.09, 1984.93 ± 5.36, and 1274.25 ± 57.16,
respectively (Figure 12). For liver metastatic tumors, the corresponding
IOD values were 2115.96 ± 107.93, 2103.45 ± 31.17, and 575.97 ±
13.76, respectively. As shown in Figures 11 and 12, VEGF staining
was much higher in subcutaneous tumor and liver metastasis tumors
of SW620 and negative group (HK) (P > .05). In contrast, VEGF
staining was significantly decreased in SihVEGF-4 group both in sub-
cutaneous and liver metastasis tumors (P < .001).
Discussion
VEGF is one of the most important angiogenic factors. Its role in
angiogenesis and tumor development, growth, and metastasis has
been well documented [15,16]. When secreted by tumor cells, it
acts in a paracrine fashion to stimulate proliferation of endothelial
cells [22]. Although endothelial cells are the primary targets of
Figure 7. Effects of VEGF siRNA on tumor cell invasion and angio-
genesis in vitro. (A) Tumor cell invasion. *P > .05, P < .001.
(B) Angiogenesis in vitro. *P > .05, P < .001.
Figure 8. Effects of VEGF siRNA on tumor growth in vivo. (A) Subcutaneous tumor model: SW620 group (a, b, c; n = 3), HK group (d, e,
f; n = 3), and SihVEGF-4 group (g, h, i; n = 3). (B) Tumor growth curves of each group over 28 days. *P > .05, P < .001.
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VEGF, several studies have also reported its mitogenic effects on
certain nonendothelial cells, such as retinal pigment epithelial cells
[23], pancreatic duct cells [24], and Schwann cells [25]; as well as
on cancer cells, including breast cancer [26–28], prostate cancer
[29,30], and gastric adenocarcinoma [31]. These findings have led
us to hypothesize that an autocrine loop exists whereby VEGF stimu-
lates tumor growth not only by interacting with endothelial cells but
also by binding directly to the VEGF receptor (VEGFR) on tumor cells.
The present study demonstrated that RNA interference against
VEGF successfully inhibited the expression and secretion of VEGF
in human CRC SW620 cells, leading to a potent suppression of tu-
mor cell proliferation, migration, invasion, angiogenesis in vitro and
in vivo, as well as tumor growth, and metastasis in a xenograft tumor
model. These findings not only demonstrate that VEGF plays a crit-
ical role in colon cancer cell proliferation, migration, and invasion
but also suggest that a VEGF-mediated autocrine loop is a significant
factor affecting tumor growth and metastasis.
Recent reports by Detwiller et al. [15] and Guan et al. [16] dem-
onstrate that siRNA-targeting VEGF decrease sarcoma growth
in vivo but have no effect on cellular proliferation in vitro. In the pres-
ent study, we have found that the VEGF siRNA suppresses not only
the proliferation of SW620 cells but also their ability to migrate and
invade. The effects on proliferation, migration, and invasion appear
to be a direct effect of the decreased production of VEGF by these
cells. Our findings and previous studies [32,33] support the idea that
there may be a VEGF-directed autocrine loop directly affecting colon
cancer cell growth and function. Studies suggest that mechanisms of
VEGF/VEGFR interaction may involve the cyclooxygenase-2 inhibi-
tor and activation of the Src family [32,33], but the specific mecha-
nisms of VEGF/VEGFR interaction in both endothelial and tumor
cells remain unclear. More research is needed to delineate the signaling
pathways mediated by VEGFRs.
Even with a nearly complete abrogation of VEGF protein secre-
tion, SW620 cells still formed tumors in mice, albeit at a significantly
slower rate. This indicates that there may be several additional mech-
anisms involved in angiogenesis that is stimulated in VEGF-silenced
tumors. For instance, tumors may induce surrounding stromal cells
to secrete VEGF. It has been shown in tumors derived from VEGF-
null embryonic stem cells that VEGF-A from tumor stroma can sup-
port tumor vascularization [33]. Perhaps RNAi targeting multiple
angiogenic factors could completely abrogate new blood vessel for-
mation and tumor growth.
In considering RNAi as a therapeutic tool, one must consider
methods of delivery, because the efficacy and mode of delivery of
siRNA vary considerably [34]. Chemically or enzymatically synthe-
sized siRNA is costly and has been shown to have a relatively short
half-life, with only transient inhibition of target genes [35]. These
and other problems have been addressed through changes in how
the RNAi is delivered. For example, repeated administration of siRNA
can compensate for the reagent’s short half-life. In addition, the use of
ligand-directed nanoparticles has shown promise in addressing other
RNAi issues, such as cellular uptake, nonspecific immune stimula-
tion, and limited stability [36]. The present study corroborates other
Figure 9. Effects of VEGF siRNA on tumor metastasis in vivo. (A) Liver metastasis model: SW620 group (a, b, c; n = 3), HK group (d, e, f;
n= 3), and SihVEGF-4 group (g, h, i; n = 3). Arrow shows metastasis in SihVEGF-4 group (1/3). (B) Body weight change in SW620 group,
HK group, and SihVEGF-4 group over 35 days. *P > .05, P < .05.
Figure 10. Effects of VEGF siRNA on tumor angiogenesis in vivo.
The MVD values (per 200× field) of subcutaneous and metastatic
tumors are as follows: SW620 group: 14 ± 2 (subcutaneous) vs
17 ± 2 (metastatic tumor); HK group: 12 ± 1 (subcutaneous) vs
15 ± 3 (metastasis); SihVEGF-4 group: 4 ± 1 (subcutaneous)
vs 7 ± 2 (metastatic). *P > .05, P < .001.
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work [37,38] to highlight another technique: the use of plasmid and
viral vectors to produce siRNA using the polymerase III promoter.
This approach may offer more efficient siRNA delivery and can theo-
retically induce stable gene silencing.
In summary, the present study demonstrated that vector-mediated
RNA interference of VEGF successfully inhibited the expression of
VEGF in in vitro and in vivo models of human CRC, leading to sev-
eral antitumor activities such as inhibitory effects on cell prolifera-
tion, migration, invasion, angiogenesis, tumor growth, and
metastasis. These findings suggest that the RNAi approach can be
an effective therapeutic strategy for CRC. The present study provides
a basis for future studies of this approach in additional animal models
and in human clinical trials.
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